scholarly journals Inactivation and Removal of Chikungunya Virus and Mayaro Virus from Plasma-derived Medicinal Products

Viruses ◽  
2019 ◽  
Vol 11 (3) ◽  
pp. 234 ◽  
Author(s):  
Constanze Yue ◽  
Sebastian Teitz ◽  
Tomoyuki Miyabashi ◽  
Klaus Boller ◽  
Lia Lewis-Ximenez ◽  
...  
Keyword(s):  
Chikungunya Virus ◽  
Febrile Illness ◽  
Heat Inactivation ◽  
Medicinal Products ◽  
Emerging Viruses ◽  
Viral Inactivation ◽  
Detergent Treatment ◽  
Mayaro Virus ◽  
Almost All ◽  
Product Industry

Background: Chikungunya virus (CHIKV) and Mayaro virus (MAYV) are closely related members of the Semliki Forest complex within the genus alphavirus and are transmitted by arthropods, causing acute febrile illness in humans. CHIKV has spread to almost all continents, whereas autochthonous MAYV infections have been reported in South America and in the Caribbean. Nevertheless, there was concern about potential spread of MAYV to other regions similar to CHIKV in the past. The risk for transmission of emerging viruses by blood transfusion and the safety of plasma-derived medicinal products (PDMPs) are constant concerns. The manufacturing processes of PDMPs include procedures to inactivate/remove viruses. Methods: In this study, we investigated the reduction of MAYV and CHIKV by heat inactivation in various matrices, solvent/detergent treatment and nanofiltration. Results: Unexpectedly, MAYV was significantly more resistant to heat and solvent/detergent treatment compared to CHIKV. However, being similar in size, both MAYV and CHIKV were removed below the detection limit by 35 nm virus filters. Conclusions: The inactivation profiles of different alphavirus members vary considerably, even within the Semliki Forest Complex. However, robust dedicated viral inactivation/removal procedures commonly used in the plasma product industry are effective in inactivating or removing MAYV and CHIKV.

scholarly journals Dengue fever and chikungunya virus infections: identification in travelers in Uganda – 2017

2019 ◽  
Vol 5 (1) ◽  
Author(s):  
John T. Kayiwa ◽  
Annet M. Nankya ◽  
Irene Ataliba ◽  
Charity A. Nassuna ◽  
Isaac E. Omara ◽  
...  
Keyword(s):  
Public Health ◽  
Dengue Fever ◽  
Chikungunya Virus ◽  
Clinical Manifestations ◽  
Febrile Illness ◽  
Final Diagnosis ◽  
Differential Diagnoses ◽  
Global Public Health ◽  
Emerging Viruses ◽  
Public Health Importance

AbstractArboviruses are (re-) emerging viruses that cause significant morbidity globally. Clinical manifestations usually consist of a non-specific febrile illness that may be accompanied by rash, arthralgia and arthritis and/or with neurological or hemorrhagic syndromes. The broad range of differential diagnoses of other infectious and non-infectious etiologies presents a challenge for clinicians. While knowledge of the geographic distribution of pathogens and the current epidemiological situation, incubation periods, exposure risk factors and vaccination history can help guide the diagnostic approach, the non-specific and variable clinical presentation can delay final diagnosis. This case report summarizes the laboratory-based findings of three travel-related cases of arbovirus infections in Uganda. These include a patient from Bangladesh with chikungunya virus infection and two cases of dengue fever from Ethiopia. Early detection of travel-imported cases by public health laboratories is important to reduce the risk of localized outbreaks of arboviruses such as dengue virus and chikungunya virus. Because of the global public health importance and the continued risk of (re-) emerging arbovirus infections, specific recommendations following diagnosis by clinicians should include obtaining travel histories from persons with arbovirus-compatible illness and include differential diagnoses when appropriate.

scholarly journals Extracellular Vesicles Analysis in the COVID-19 Era: Insights on Serum Inactivation Protocols towards Downstream Isolation and Analysis

Cells ◽  
2021 ◽  
Vol 10 (3) ◽  
pp. 544
Author(s):  
Roberto Frigerio ◽  
Angelo Musicò ◽  
Marco Brucale ◽  
Andrea Ridolfi ◽  
Silvia Galbiati ◽  
...  
Keyword(s):  
Extracellular Vesicles ◽  
Analytical Techniques ◽  
Heat Inactivation ◽  
Force Microscopy ◽  
Atomic Force ◽  
Droplet Pcr ◽  
Detergent Treatment ◽  
Routine Procedures ◽  
The Impact ◽  
Mirna Content

Since the outbreak of the COVID-19 crisis, the handling of biological samples from confirmed or suspected SARS-CoV-2-positive individuals demanded the use of inactivation protocols to ensure laboratory operators’ safety. While not standardized, these practices can be roughly divided into two categories, namely heat inactivation and solvent-detergent treatments. These routine procedures should also apply to samples intended for Extracellular Vesicles (EVs) analysis. Assessing the impact of virus-inactivating pre-treatments is therefore of pivotal importance, given the well-known variability introduced by different pre-analytical steps on downstream EVs isolation and analysis. Arguably, shared guidelines on inactivation protocols tailored to best address EVs-specific requirements will be needed among the analytical community, yet deep investigations in this direction have not yet been reported. We here provide insights into SARS-CoV-2 inactivation practices to be adopted prior to serum EVs analysis by comparing solvent/detergent treatment vs. heat inactivation. Our analysis entails the evaluation of EVs recovery and purity along with biochemical, biophysical and biomolecular profiling by means of a set of complementary analytical techniques: Nanoparticle Tracking Analysis, Western Blotting, Atomic Force Microscopy, miRNA content (digital droplet PCR) and tetraspanin assessment by microarrays. Our data suggest an increase in ultracentrifugation (UC) recovery following heat treatment; however, it is accompanied by a marked enrichment in EVs-associated contaminants. On the other hand, solvent/detergent treatment is promising for small EVs (<150 nm range), yet a depletion of larger vesicular entities was detected. This work represents a first step towards the identification of optimal serum inactivation protocols targeted to EVs analysis.

scholarly journals Chikungunya: epidemiology

F1000Research ◽  
2016 ◽  
Vol 5 ◽  
pp. 82 ◽  
Author(s):  
Lyle R. Petersen ◽  
Ann M. Powers
Keyword(s):  
Public Health ◽  
Aedes Aegypti ◽  
Aedes Albopictus ◽  
Chikungunya Virus ◽  
Mosquito Species ◽  
Febrile Illness ◽  
Current Understanding ◽  
Global Public Health ◽  
Temperate Climates

Chikungunya virus is a mosquito-borne alphavirus that causes fever and debilitating joint pains in humans. Joint pains may last months or years. It is vectored primarily by the tropical and sub-tropical mosquito, Aedes aegypti, but is also found to be transmitted by Aedes albopictus, a mosquito species that can also be found in more temperate climates. In recent years, the virus has risen from relative obscurity to become a global public health menace affecting millions of persons throughout the tropical and sub-tropical world and, as such, has also become a frequent cause of travel-associated febrile illness. In this review, we discuss our current understanding of the biological and sociological underpinnings of its emergence and its future global outlook.

scholarly journals Human IFITM3 restricts Chikungunya virus and Mayaro virus infection and is susceptible to virus-mediated counteraction

2020 ◽  
Author(s):  
Sergej Franz ◽  
Thomas Zillinger ◽  
Fabian Pott ◽  
Christiane Schüler ◽  
Sandra Dapa ◽  
...  
Keyword(s):  
Virus Infection ◽  
Influenza A ◽  
Chikungunya Virus ◽  
Protein S ◽  
Human Cells ◽  
Structural Protein ◽  
Infected Cells ◽  
Mayaro Virus ◽  
The Impact

AbstractInterferon-induced transmembrane (IFITM) proteins restrict infection by enveloped viruses through interfering with membrane fusion and virion internalisation. The role of IFITM proteins during alphaviral infection of human cells and viral counteraction strategies remain largely unexplored. Here, we characterized the impact of IFITM proteins and variants on entry and spread of Chikungunya virus (CHIKV) and Mayaro virus (MAYV) in human cells, and provide first evidence for a CHIKV-mediated antagonism of IFITM proteins. IFITM1, 2 and 3 restricted infection at the level of alphavirus glycoprotein-mediated entry, both in the context of direct infection and during cell-to-cell transmission. Relocalization of normally endosomal IFITM3 to the plasma membrane resulted in the loss of its antiviral activity. rs12252-C, a naturally occurring variant of IFITM3 that has been proposed to associate with severe influenza in humans, restricted CHIKV, MAYV and influenza A virus infection as efficiently as wild-type IFITM3. Finally, all antivirally active IFITM variants displayed reduced cell surface levels in CHIKV-infected cells involving a posttranscriptional process mediated by one or several non-structural protein(s) of CHIKV.

scholarly journals Unusual Presentation of Chikungunya Virus Infection With Concomintant Erysipelas in a Returning Traveler From the Caribbean: A Case Report

2014 ◽  
Vol 1 (3) ◽  
Author(s):  
Marcos C. Schechter ◽  
Kimberly A. Workowski ◽  
Jessica K. Fairley
Keyword(s):  
United States ◽  
Case Report ◽  
Virus Infection ◽  
Aedes Albopictus ◽  
Chikungunya Virus ◽  
Febrile Illness ◽  
Unusual Presentation ◽  
Chikungunya Fever ◽  
The Caribbean ◽  
Local Transmission

Abstract Chikungunya fever is a mosquito-borne febrile illness caused by Chikungunya virus (CHIKV), an alphavirus from the Togaviridae family. It is transmitted by primarily Aedes aegytpi and Aedes albopictus mosquitos [1]. Once of little importance in the Americas, local transmission was identified in the Caribbean in late 2013. More than 1000 travelers returning to the continental United States have been diagnosed with CHIKV. More importantly, there have been 9 documented cases of autochthonous disease in Florida as of September 16, 2014 [2].

scholarly journals Zika Virus: Diagnostics for an Emerging Pandemic Threat

2016 ◽  
Vol 54 (4) ◽  
pp. 860-867 ◽  
Author(s):  
Jesse J. Waggoner ◽  
Benjamin A. Pinsky
Keyword(s):  
Dengue Virus ◽  
Zika Virus ◽  
Chikungunya Virus ◽  
Febrile Illness ◽  
Zikv Infection ◽  
Content Type ◽  
Clinical Criteria ◽  
Virus Diagnostics ◽  
Pandemic Threat

Zika virus (ZIKV) is anAedesmosquito-borne flavivirus that emerged in Brazil in 2015 and then rapidly spread throughout the tropical and subtropical Americas. Based on clinical criteria alone, ZIKV cannot be reliably distinguished from infections with other pathogens that cause an undifferentiated systemic febrile illness, including infections with two common arboviruses, dengue virus and chikungunya virus. This minireview details the methods that are available to diagnose ZIKV infection.

scholarly journals Characterization of Unknown Orthobunya-Like Viruses from India

Viruses ◽  
2018 ◽  
Vol 10 (9) ◽  
pp. 451 ◽  
Author(s):  
Shannon Whitmer ◽  
Pragya Yadav ◽  
Prasad Sarkale ◽  
Gouri Chaubal ◽  
Alicia Francis ◽  
...  
Keyword(s):  
Next Generation Sequencing ◽  
Febrile Illness ◽  
Geographic Region ◽  
Emerging Viruses ◽  
Simbu Serogroup ◽  
Isolation And Characterization ◽  
Karnataka State ◽  
Next Generation Sequencing Ngs ◽  
Generation Sequencing

Next-generation sequencing (NGS) of agents causing idiopathic human diseases has been crucial in the identification of novel viruses. This study describes the isolation and characterization of two novel orthobunyaviruses obtained from a jungle myna and a paddy bird from Karnataka State, India. Using an NGS approach, these isolates were classified as Cat Que and Balagodu viruses belonging to the Manzanilla clade of the Simbu serogroup. Closely related viruses in the Manzanilla clade have been isolated from mosquitos, humans, birds, and pigs across a wide geographic region. Since Orthobunyaviruses exhibit high reassortment frequency and can cause acute, self-limiting febrile illness, these data suggest that human and livestock infections of the Oya/Cat Que/Manzanilla virus may be more widespread and/or under-reported than anticipated. It therefore becomes imperative to identify novel and unknown viruses in order to understand their role in human and animal pathogenesis. The current study is a step forward in this regard and would act as a prototype method for isolation, identification and detection of several other emerging viruses.

Serological Responses in Patients Infected with Mayaro Virus and Evaluation of Cross-Protective Responses against Chikungunya Virus

2021 ◽  
Author(s):  
Nathen E. Bopp ◽  
Kara J. Jencks ◽  
Crystyan Siles ◽  
Carolina Guevara ◽  
Stalin Vilcarromero ◽  
...  
Keyword(s):  
Latin America ◽  
South America ◽  
Neutralizing Antibodies ◽  
Chikungunya Virus ◽  
Neutralization Test ◽  
Close Relative ◽  
Previous Exposure ◽  
Chikv Infection ◽  
The Caribbean ◽  
Mayaro Virus

Mayaro virus (MAYV) is an alphavirus endemic to both Latin America and the Caribbean. Recent reports have questioned the ability of MAYV and its close relative, Chikungunya virus (CHIKV), to generate cross-reactive, neutralizing antibodies to one another. Since CHIKV was introduced to South America in 2013, discerning whether individuals have cross-reactive antibodies or whether they have had exposures to both viruses previously has been difficult. Using samples obtained from people infected with MAYV prior to the introduction of CHIKV in the Americas, we performed neutralizing assays and observed no discernable neutralization of CHIKV by sera from patients previously infected with MAYV. These data suggest that a positive CHIKV neutralization test cannot be attributed to prior exposure to MAYV and that previous exposure to MAYV may not be protective against a subsequent CHIKV infection.

scholarly journals Global distribution and environmental suitability for chikungunya virus, 1952 to 2015

2016 ◽  
Vol 21 (20) ◽  
Author(s):  
Elaine O Nsoesie ◽  
Moritz UG Kraemer ◽  
Nick Golding ◽  
David M Pigott ◽  
Oliver J Brady ◽  
...  
Keyword(s):  
At Risk ◽  
Chikungunya Virus ◽  
Febrile Illness ◽  
Good Evidence ◽  
Global Distribution ◽  
Contributing Factors ◽  
Chikungunya Fever ◽  
Distribution Maps ◽  
Environmental Suitability ◽  
Modelling Framework

Chikungunya fever is an acute febrile illness caused by the chikungunya virus (CHIKV), which is transmitted to humans by Aedes mosquitoes. Although chikungunya fever is rarely fatal, patients can experience debilitating symptoms that last from months to years. Here we comprehensively assess the global distribution of chikungunya and produce high-resolution maps, using an established modelling framework that combines a comprehensive occurrence database with bespoke environmental correlates, including up-to-date Aedes distribution maps. This enables estimation of the current total population-at-risk of CHIKV transmission and identification of areas where the virus may spread to in the future. We identified 94 countries with good evidence for current CHIKV presence and a set of countries in the New and Old World with potential for future CHIKV establishment, demonstrated by high environmental suitability for transmission and in some cases previous sporadic reports. Aedes aegypti presence was identified as one of the major contributing factors to CHIKV transmission but significant geographical heterogeneity exists. We estimated 1.3 billion people are living in areas at-risk of CHIKV transmission. These maps provide a baseline for identifying areas where prevention and control efforts should be prioritised and can be used to guide estimation of the global burden of CHIKV.

scholarly journals Effects of Chikungunya virus immunity on Mayaro virus disease and epidemic potential

2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Emily M. Webb ◽  
Sasha R. Azar ◽  
Sherry L. Haller ◽  
Rose M. Langsjoen ◽  
Candace E. Cuthbert ◽  
...  
Keyword(s):  
Neutralizing Antibodies ◽  
Chikungunya Virus ◽  
Semliki Forest Virus ◽  
Virus Disease ◽  
Cross Protection ◽  
Health Concern ◽  
Antigenic Relationship ◽  
Wild Type ◽  
Chikv Infection ◽  
Mayaro Virus

AbstractMayaro virus (MAYV) causes an acute febrile illness similar to that produced by chikungunya virus (CHIKV), an evolutionary relative in the Semliki Forest virus complex of alphaviruses. MAYV emergence is typically sporadic, but recent isolations and outbreaks indicate that the virus remains a public health concern. Given the close phylogenetic and antigenic relationship between CHIKV and MAYV, and widespread distribution of CHIKV, we hypothesized that prior CHIKV immunity may affect MAYV pathogenesis and/or influence its emergence potential. We pre-exposed immunocompetent C57BL/6 and immunocompromised A129 or IFNAR mice to wild-type CHIKV, two CHIKV vaccines, or a live-attenuated MAYV vaccine, and challenged with MAYV. We observed strong cross-protection against MAYV for mice pre-exposed to wild-type CHIKV, and moderately but significantly reduced cross-protection from CHIKV-vaccinated animals. Immunity to other alphavirus or flavivirus controls provided no protection against MAYV disease or viremia. Mechanistic studies suggested that neutralizing antibodies alone can mediate this protection, with T-cells having no significant effect on diminishing disease. Finally, human sera obtained from naturally acquired CHIKV infection cross-neutralized MAYV at high titers in vitro. Altogether, our data suggest that CHIKV infection can confer cross-protective effects against MAYV, and the resultant reduction in viremia may limit the emergence potential of MAYV.

Sign in / Sign up

Export Citation Format

Share Document